Endurance Wealth Management’s Ginkgo Bioworks DNA Stock Holding History

Endurance Wealth Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$37K	Hold	500	–	–	0.01%	370
2023 Q1	$27K	Buy	500 +250	+100%	+$15.8K	﹤0.01%	409
2022 Q4	$17K	Hold	250	–	–	﹤0.01%	424
2022 Q3	$31K	Hold	250	–	–	0.01%	371
2022 Q2	$24K	Hold	250	–	–	﹤0.01%	395
2022 Q1	$40K	Buy	250 +125	+100%	+$24.3K	0.01%	376
2021 Q4	$42K	Buy	125 +75	+150%	+$35.6K	﹤0.01%	369
2021 Q3	$23K	Buy	+50	New	+$24.3K	﹤0.01%	434

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Endurance Wealth Management's DNA Position: Q2 2023 in Review

Endurance Wealth Management held its Ginkgo Bioworks (DNA) position steady in Q2 2023 at 500 shares worth $37K. The position accounts for 0.01% of the portfolio, ranked #370.

Endurance Wealth Management first reported a position in DNA in Q3 2021 and has held it in 8 quarters since. The position peaked at $42K in Q4 2021. 315 funds tracked by Wall St. Rank hold DNA as of Q2 2023.

Endurance Wealth Management held 500 shares of Ginkgo Bioworks worth $37K as of Q2 2023.
Endurance Wealth Management left its Ginkgo Bioworks share count unchanged in Q2 2023.
Ginkgo Bioworks made up 0.01% of Endurance Wealth Management's portfolio in Q2 2023, its #370 holding.
Endurance Wealth Management first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 8 quarters since.
Endurance Wealth Management's Ginkgo Bioworks position peaked at $42K in Q4 2021.
315 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.